LEXETTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LEXETTE (LEXETTE).
LEXETTE (halobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects. The primary mechanism involves binding to glucocorticoid receptors, which modulates gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
| Metabolism | Hepatic metabolism via CYP450 enzymes, primarily CYP3A4. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 70%), with 30% metabolized hepatically via CYP3A4 and excreted as inactive metabolites in urine and feces. |
| Half-life | Terminal elimination half-life is 12-15 hours, supporting twice-daily dosing in clinical practice. |
| Protein binding | Highly protein-bound (95-99%), primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.5-1.2 L/kg, indicating extensive tissue penetration. |
| Bioavailability | Oral bioavailability low (<5%) due to extensive first-pass metabolism; topical bioavailability negligible systemically (<1%). |
| Onset of Action | Topical administration: Clinical improvement observed within 1-2 weeks; systemic absorption minimal. |
| Duration of Action | Duration of therapeutic effect after topical application is approximately 12 hours, consistent with dosing interval. Continuous use recommended for sustained efficacy. |
| Molecular Weight | 376.45 |
Apply to affected areas once daily for up to 2 weeks. Use no more than 60 g per week.
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for use in pediatric patients safety and efficacy not established. |
| Geriatric use | No dose adjustment required; caution due to potential for increased skin atrophy or systemic effects. |
| 1st trimester | Insufficient data in pregnant women. Animal studies show no teratogenic effects but doses equivalent to human therapeutic exposure. Use only if benefit justifies risk. |
| 2nd trimester | Avoid unless clearly needed. Systemic absorption may affect fetal growth. Short-term, minimal exposure advised. |
| 3rd trimester | Avoid during third trimester due to potential for premature closure of ductus arteriosus and oligohydramnios. Fetal renal effects possible. |
Clinical note
Comprehensive clinical and safety monograph for LEXETTE (LEXETTE).
| Placental transfer | Predicted to cross placenta based on molecular weight and lipophilicity; no direct human data. Animal studies indicate transfer. |
| Breastfeeding | Not recommended during breastfeeding. Systemic absorption is low but may cause adverse effects in infant (e.g., adrenal suppression). Use only if alternative unavailable and discontinue or wean. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to active substance or excipientsFungal infections at treatment site (unless concurrently treated)Occlusive dressings (increased absorption risk)
| Precautions | Reversible HPA axis suppression with potential for glucocorticoid insufficiency after withdrawal, Systemic absorption may cause Cushing's syndrome, hyperglycemia, and unmask latent diabetes, Local adverse reactions including atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and maceration, Use with caution on face, intertriginous areas, and under occlusive dressings, Avoid use in patients with known hypersensitivity to halobetasol propionate or any component of the formulation |
| Food/Dietary | No known food interactions. No dietary restrictions required. |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | LEXETTE (clobetasol propionate foam, 0.05%) is a super-high potency topical corticosteroid. Systemic absorption is minimal with topical use, but increased with application to large areas, occlusive dressings, or damaged skin. In animal reproduction studies, corticosteroids have been shown to be teratogenic (cleft palate, skeletal anomalies) following systemic administration at relatively low doses. However, there are no adequate and well-controlled studies in pregnant women. The potential risk to the fetus is considered low with proper topical use, but use during pregnancy should be limited to the smallest amount for the shortest duration. First trimester: risk cannot be ruled out; avoid if possible. Second and third trimesters: use only if clearly needed and only on small areas for brief periods. |
| Fetal Monitoring | No specific maternal or fetal monitoring is routinely required for LEXETTE during pregnancy. However, if used extensively, on large areas, or for prolonged periods, consider monitoring for signs of maternal adrenal suppression (e.g., morning cortisol, ACTH stimulation test). Fetal growth and development should be followed by routine prenatal care. Avoid use in high doses or on large areas to minimize systemic absorption. |
| Fertility Effects | No fertility studies have been conducted with topical clobetasol propionate. Systemically administered corticosteroids have been shown to impair fertility in some animal studies. Given the low systemic absorption with proper topical use, significant effects on human fertility are unlikely. However, if used excessively, potential for hypothalamic-pituitary-adrenal (HPA) axis suppression could theoretically affect reproductive function. |
| Clinical Pearls | LEXETTE (halobetasol propionate 0.01% lotion) is a super-high-potency topical corticosteroid for plaque psoriasis. Limit application to 2 consecutive weeks; total dose should not exceed 50 g/week (or 50 mL/week). Do not use on face, groin, axillae, or under occlusion unless directed. Reassess if no improvement after 2 weeks. |
| Patient Advice | Apply a thin layer to affected areas only, once daily; do not use more than instructed. · Do not use on face, underarms, or groin unless told by your doctor. · Wash hands after application unless treating hands. · Avoid contact with eyes and mouth; if accidental contact occurs, rinse thoroughly with water. · Do not cover treated areas with bandages or dressings unless directed. · Do not use more than 50 mL per week; treatment should not exceed 2 weeks. · Inform doctor if no improvement after 2 weeks or if condition worsens. · Avoid using other corticosteroid products without consulting your doctor. |